Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition

Pepper, C., Buggins, A. G.S., Jones, C. H., Walsby, E. J. ORCID: https://orcid.org/0000-0001-8523-5017, Forconi, F., Pratt, G., Devereux, S., Stevenson, F. and Fegan, C. ORCID: https://orcid.org/0000-0001-9685-0621 2015. Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition. Leukemia 29 , pp. 744-747. 10.1038/leu.2014.308

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (425kB) | Preview

Abstract

The majority of chronic lymphocytic leukemia (CLL) patients are diagnosed with early-stage disease but the currently used prognostic tools appear to be less informative in this group of patients.1 This is especially problematic for patients with mutated immunoglobulin genes (M-CLL) as they have a more diverse clinical course when compared with patients with unmutated immunoglobulin genes (U-CLL).1, 2, 3, 4 Given the emergence of promising targeted, less toxic, therapeutics in CLL,5, 6 there is an increased need to identify patients who might benefit from early treatment with these new agents.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Additional Information:	This work is licensed under a Creative Commons Attribution 4.0 International License.
Publisher:	Springer Nature
ISSN:	0887-6924
Funders:	Leukaemia & Lymphoma Research, Leukaemia Research Appeal for Wales, NISCHR, Global CLL Research Foundation
Date of First Compliant Deposit:	30 March 2016
Date of Acceptance:	20 October 2014
Last Modified:	05 Aug 2023 17:35
URI:	https://orca.cardiff.ac.uk/id/eprint/67297

Citation Data

Cited 19 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item